Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01449955|
Recruitment Status : Completed
First Posted : October 10, 2011
Results First Posted : January 30, 2014
Last Update Posted : March 28, 2014
The purpose of the proposed study is to determine if pairing reactivation of a traumatic memory with a single administration of Rapamycin (e.g., Sirolimus) in men with combat-related Posttraumatic Stress Disorder leads to a reduction of the emotional strength of that particular traumatic memory.
The following hypotheses will be tested:
- Traumatic memory reactivation paired with a single dose of Rapamycin will decrease objective measures of stress and self-report of stress during replay of the traumatic memory, relative to, subjects receiving placebo.
- Pairing administration of Rapamycin with traumatic memory reactivation will decrease symptoms of Posttraumatic Stress Disorder one month and three months later, relative to patients receiving placebo.
|Condition or disease||Intervention/treatment|
|Posttraumatic Stress Disorder||Drug: Rapamycin Drug: Placebo|
Post-traumatic stress disorder (PTSD) is characterized by intrusive memories in the form of unwanted images, nightmares, and flashbacks as the result of being exposed to a traumatic event . Current research efforts have begun to explore the underlying neurochemical changes associated with PTSD. Recently, these efforts have focused on the prevention of PTSD in persons exposed to trauma. For example, preliminary evidence suggests that interference with consolidation of trauma-related memories using the beta-antagonist, propranolol, may prevent PTSD in humans with recent traumas. However, given that as much as 90% of the US population is exposed to at least one traumatic event during their lifetimes, the utility of this treatment is limited by the logistical problems of treating everyone at risk. To date, there have been very few systematic studies on humans that focus on changing the underlying traumatic memory once PTSD has been established.
The trauma experience is initially stored in short-term memory, then consolidated into long-term memory. However, the long-term stability conferred by the consolidation process undergoes a period of labiality as follows. Each time a consolidated memory is activated, the memory trace becomes newly labile and must be consolidated again to remain in long-term memory5. This process is called reconsolidation. Reconsolidation therefore offers a biologic window during which long-term memories can be disrupted. Preclinical studies have begun to unravel the biological changes that underlie these processes. Both pharmacological agents, including glucocorticoids, and protein synthesis inhibitors can interfere with memory consolidation and reconsolidation. In preclinical studies, the global protein synthesis inhibitor anisomycin can block reconsolidation, leading to a reduction in strength of traumatic memories. Unfortunately, the toxicity of anisomycin is prohibitive for therapeutic use. Thus, rather than using a global protein synthesis inhibitor, a more effective and selective means of reducing consolidation of an established traumatic memory is to target only a subset of protein translation important for synaptic plasticity. The protein kinase mTOR (mammalian target of rapamycin) is just such a regulator of a subset of protein synthesis critical for synaptic plasticity.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||54 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||mTOR Kinase as a Therapeutic Target in Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory|
|Study Start Date :||August 2008|
|Primary Completion Date :||July 2010|
|Study Completion Date :||July 2010|
Placebo Comparator: Placebo (e.g., sugar pill)
15 mg Placebo will be administered once, in pill form.
Other Name: sugar pill
Active Comparator: Rapamycin
15 mg of Rapamycin will be administered once, in pill form.
Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.
a single dosage of 15mg will be administered during this study.
- Clinician Administered Posttraumatic Stress Disorder Scale (CAPS) [ Time Frame: Baseline and 1 month posttreatment ]Clinician administered interview which assesses the symptoms of Posttraumatic Stress disorder at baseline, and then again 1 month posttreatment. The CAPS is a 25 item semi-structured interview that assesses the 17 DSM-IV PTSD criteria as well as social and occupational impairment. For each item the participant can respond with a rating of 0-8 (with 0 indicating no symptom severity and frequency and 8 indicating extreme symptom severity and frequency). The range of total scores on a CAPS is from 0-136, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items. Additionally, the CAPS assesses for a positive PTSD diagnosis by assessing for the three DSM-IV criteria of B, C, and D. In order to meet a positive screen for each criteria, a person must screen positive for symptoms by reporting a score of 3 or more on the specific symptom criterion.
- Clinician Administered Posttraumatic Stress Disorder Scale (CAPS) [ Time Frame: change in CAPS score from baseline to 3 months posttreatment ]The CAPS is administered to assess the frequency and intensity of PTSD symptoms at baseline, and then again 3 months posttreatment.
- PTSD Checklist (PCL) [ Time Frame: change in PCL score from baseline to 1 month posttreatment ]Self-report measure of the intensity of PTSD symptoms
- PTSD Checklist (PCL) [ Time Frame: change in PCL score from baseline to 3 months posttreatment ]Self-report measure of the intensity of PTSD symptoms
- Quick Inventory of Depressive Symptomatology (QIDS) [ Time Frame: change in QIDS score from baseline to 1 month posttreatment ]Self-report measure of depressive symptoms
- Quick Inventory of Depressive Symptomatology (QIDS) [ Time Frame: change in QIDS score from baseline to 3 months posttreatment ]Self-report measure of depressive symptoms
- Quick Inventory of Depressive Symptomatology (QIDS) [ Time Frame: change in QIDS score from baseline to 1 week posttreatment ]Self-report measure of depressive symptoms
- Psychophysiology Measurements: Heart Rate [ Time Frame: one week after medication ]The participant's heart rate is monitored during a script-driven imagery procedure. This procedure involves listening to 4 scripts: 2 neutral, 2 combat-related.
- Psychophysiology Measurements: Skin Conductance [ Time Frame: one week after medication ]The participant's skin conductance response is monitored during a script-driven imagery procedure. This procedure involves listening to 4 scripts: 2 neutral, 2 combat-related
- Psychophysiological Measurements: Electromyogram [ Time Frame: one week after medication ]The participant's left lateral frontalis and left corrugator muscle activity is monitored during a script-driven imagery procedure. This procedure involves listening to 4 scripts: 2 neutral, 2 combat-related
- PTSD Checklist (PCL) [ Time Frame: change in PCL score from baseline to one week posttreatment ]Self-report measure of the intensity of PTSD symptoms
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01449955
|United States, Texas|
|VA North Texas Healthcare System|
|Dallas, Texas, United States, 75216|
|Principal Investigator:||Alina M Suris, Ph.D.||UT Southwestern Medical Center; VA North Texas Healthcare System|
|Study Chair:||Carol North, M.D.||UT Southwestern Medical Center; VA North Texas Healthcare System|